Recruiting
Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed after, CAR T-cell therapy.
2025-523428-39-00· Phase 2· Fondazione Italiana Linfomi Ets· Source
Recruiting
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
2025-521074-34-00· Phase 2· Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare· Source
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· Phase 3· Syndax Pharmaceuticals· Source
Not yet recruiting
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
NCT06880601· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Not yet recruiting
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
NCT06667973· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· Phase 3· Takeda· Source
Active, not recruiting
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
NCT05605899· Phase 3· Kite Pharma Inc.· Source
Recruiting
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)
2024-515252-20-00· Phase 1/2· iOnctura SA· Source
Recruiting
Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes.
NCT02912208· Phase 2· Associazione Qol-One· Source
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· Phase 3· Incyte Corporation· Source
Recruiting
MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 translational study.
NCT04091204· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
Exercise Activity to Improve Mobility in Patients With CKD and PAD
NCT06621264· University Hospital of Ferrara· Source
Contact: Vincenzo Panuccio Dr. Vincenzo Panuccio, MD
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961· Phase 2/3· CSL Behring· Source
Contact: Trial Registration Coordinator
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672· Phase 3· Italfarmaco· Source
Recruiting
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
NCT05694312· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Active, not recruiting
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS
2022-500430-29-00· Phase 3· Celgene Corp.· Source
Active, not recruiting
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
NCT05478512· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
NCT04662723· Phase 4· Fondazione Schena· Source
Recruiting
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
NCT05924100· Phase 2· Associazione Qol-one· Source
Contact: Esther N Oliva
Not yet recruiting
Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)
2024-520326-11-00· Phase 2· Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia· Source
Active, not recruiting
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997· Phase 3· Celgene· Source
Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632· Phase 3· Priothera SAS· Source
Contact: Maria C Mico, MD
Recruiting
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
NCT06516406· IRCCS Azienda Ospedaliero-Universitaria di Bologna· Source
Contact: Bruno Martino, MD
Active, not recruiting
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Active, not recruiting
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· Phase 3· Geron Corporation· Source
Recruiting
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
NCT04184505· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Active, not recruiting
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748· Phase 3· AbbVie· Source
Recruiting
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
NCT04332822· Phase 3· Nordic Lymphoma Group· Source
Recruiting
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.
NCT04174612· Phase 3· Fondazione G.I.M.Em.A Franco Mandelli Ets· Source
Active, not recruiting
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
NCT03610438· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919· Phase 2· Associazione Italiana Ematologia Oncologia Pediatrica· Source
Active, not recruiting
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other Luspatercept (ACE-536) clinical trials.
2022-502498-40-00· Phase 3· Celgene Corp.· Source
Recruiting
Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure
NCT04033224· Careggi Hospital· Source
Contact: Graziella Marano, MD
Active, not recruiting
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
NCT04096066· Phase 3· Fondazione EMN Italy Onlus· Source
Recruiting
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276· Phase 3· Martin Schrappe· Source
Active, not recruiting
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
NCT03246529· Phase 3· BioLineRx, Ltd.· Source